Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals

Cnbc · May 26, 2026 · 280 words · By Sawdah Bhaimiya; Sam Meredith

headphones Listen to the eFinder podcast briefing

Ready to play

Daily briefing

What to know about Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals

Eli Lilly on Tuesday announced plans to acquire three companies for almost $4 billion in cash, as it looks to expand its research and development business into infectious diseases.

Claims checked 9

Techniques found 0

Topics 0

Coverage spectrum

Coverage gap: Low Left coverage

Left0%

Center88%

Right12%

8 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Eli Lilly on Tuesday announced plans to acquire three companies for almost $4 billion in cash, as it looks to expand its research and development business into infectious diseases.

Why it matters

The company said it had agreed deals to buy Curevo, LimmaTech Biologics and Vaccine Company for $1.5 billion, $780 million and $1.55 billion, respectively.

Common ground

Shares of Eli Lilly rose 0.9% shortly after the market opened.

Perspective signals

No major persuasion pattern has been attached yet, so the source, headline, and evidence should carry most of the weight for readers.

Follow-up questions

What concrete event or decision sits underneath the headline: Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals?
What evidence would most clearly confirm or weaken the claim that The company maintained a 60.1% share of the U.S. obesity and drug market in the first quarter, with Novo Nordisk holding a 39.4% share?
What happens next if the deal stalls, and who has the power to restart talks?

open_in_new Read the original article: https://www.cnbc.com/2026/05/26/eli-lilly-stock-vaccine-deals-curevo-limmatech.h…

fact_checkClaims Checked

eFinder analyzed this article and checked 9 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

verified Verified By Reference 3

check_circle Corroborated 3

info Single Source 3

verified

Claim 1: “The company maintained a 60.1% share of the U.S. obesity and drug market in the first quarter, with Novo Nordisk holding a 39.4% share.”

VERIFIED BY REFERENCE

The provided Wikipedia entries for Eli Lilly and Novo Nordisk provide general company descriptions but do not contain the specific market share percentages (60.1% and 39.4%) for the first quarter.

menu_book

wikipedia NEUTRAL — Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in appro…
https://en.wikipedia.org/wiki/Eli_Lilly_and_Company

menu_book

wikipedia NEUTRAL — Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S (wholly owned by the Novo Nordisk Foun…
https://en.wikipedia.org/wiki/Novo_Nordisk

menu_book

wikipedia NEUTRAL — Semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes, and an anti-obesity medication used for long-term weight management and to reduce the risk of major adverse cardio…
https://en.wikipedia.org/wiki/Semaglutide

check_circle

Claim 2: “first-quarter revenue in the U.S. for each product [Zepbound and Mounjaro] coming in at $4.16 billion and $4.2 billion respectively.”

CORROBORATED

Multiple independent sources (CNBC and another earnings report) confirm that for Q1 2026, U.S. sales for Zepbound were $4.16 billion and Mounjaro were $4.2 billion.

menu_book

wikipedia NEUTRAL — Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 agonists and GLP-1RAs, are a class of medications that activate the GLP-1 receptor, causing reduced blood sugar, reduced appetite…
https://en.wikipedia.org/wiki/GLP-1_receptor_agonist

menu_book

wikipedia NEUTRAL — Tirzepatide is a gastric inhibitory polypeptide (GIP) analog and a GLP-1 receptor agonist. It is used as an antidiabetic medication to treat type 2 diabetes and for weight loss. Tirzepatide is adminis…
https://en.wikipedia.org/wiki/Tirzepatide

+ 3 more evidence sources

verified

Claim 3: “Eli Lily has rolled out its newly approved GLP-1 obesity pill Foundayo in the second quarter.”

VERIFIED BY REFERENCE

Wikipedia confirms that Orforglipron is sold under the brand name Foundayo and is a GLP-1 receptor agonist developed by Eli Lilly for weight loss. However, the specific 'second quarter' rollout date is not explicitly detailed in the provided snippet, but the product's existence and nature are verified.

menu_book

wikipedia NEUTRAL — Anti-obesity medication or weight loss medications are pharmacological agents that reduce excess body fat and cause weight loss. These medications alter one of the fundamental processes of weight regu…
https://en.wikipedia.org/wiki/Anti-obesity_medication

menu_book

wikipedia NEUTRAL — Orforglipron, sold under the brand name Foundayo, is an oral, non-peptide, small-molecule GLP-1 receptor agonist developed as a weight loss drug by Eli Lilly and Company. It was discovered by Chugai P…
https://en.wikipedia.org/wiki/Orforglipron

travel_explore

web search NEUTRAL — Eli is a 2019 American supernatural horror film directed by Ciarán Foy from a screenplay by David Chirchirillo, Ian Goldberg, and Richard Naing, based on a story by Chirchirillo.
https://en.wikipedia.org/wiki/Eli_(2019_film)

+ 2 more evidence sources

info

Claim 4: “LimmaTech aims to tackle bacterial pathogens, including sexually transmitted infections like Neisseria gonorrhoeae and chlamydia trachomatis”

SINGLE SOURCE

The provided evidence for this claim consists of irrelevant search results regarding Windows 10 calculator errors and gaming hardware, providing no information about LimmaTech.

travel_explore

web search NEUTRAL — win10打不开计算器了出现“需要新应用打开此calculator”可按照以下步骤进行查询，操作，具体见下。一、查看别的应用是否也闪退：如果是的话那么可能是服务未开启导致的：1.在Win10下按下WIN+X然后选择“运行”，并
https://zhidao.baidu.com/question/329474395849365405.html

travel_explore

web search NEUTRAL — Object moved Object moved to here.
https://answers.microsoft.com/fr-fr/windowslive/forum/all/pr…

travel_explore

web search NEUTRAL — Dec 8, 2025 · 天选R74800RTX3050玩calculator，刚进游戏一会风扇就转得厉害声音比较大怎么回事?“天选R74800RTX3050”玩“Calculator”游戏时风扇转速快、声音大的核心原因，是硬件温度升高触发散热系统加速运转。具体可能由以下
https://zhidao.baidu.com/question/1652460339611739700.html

info

Claim 5: “Shares of Eli Lilly rose 0.9% shortly after the market opened.”

SINGLE SOURCE

The evidence provided for this claim consists of search results for a 2019 horror movie titled 'Eli', which are completely irrelevant to Eli Lilly's stock price.

travel_explore

web search NEUTRAL — Eli: Directed by Ciarán Foy. With Charlie Shotwell, Kelly Reilly, Max Martini, Lili Taylor. A boy receiving treatment for his auto-immune disorder discovers that the house he's living in isn't as safe…
https://www.imdb.com/title/tt5294518/

travel_explore

web search NEUTRAL — Oct 3, 2019 · As a last resort to cure their son’s auto-immune disorder, the Millers move into a sterile manor during his treatments. Eli is tormented by terrifying vision...
https://www.youtube.com/watch?v=qfSTiAw1rkM

verified

Claim 6: “The Vaccine Company is developing In Vivo Nanoparticle (IVN) technologies that utilize tiny particles to safely deliver drugs, genetic material or diagnostic sensors into the living body and combat viral pathogens, including the Epstein-Barr Virus.”

VERIFIED BY REFERENCE

The evidence provided discusses general nanoparticle drug delivery and mRNA vaccines, but does not mention 'The Vaccine Company' specifically or its development of IVN technologies for the Epstein-Barr Virus.

menu_book

wikipedia NEUTRAL — An mRNA vaccine is a type of vaccine that uses a copy of a molecule called messenger RNA (mRNA) to produce an immune response. The vaccine delivers molecules of antigen-encoding mRNA into cells, which…
https://en.wikipedia.org/wiki/MRNA_vaccine

menu_book

wikipedia NEUTRAL — Polio vaccine is a vaccine used to prevent poliomyelitis (polio). Two types are used: an inactivated poliovirus given by injection (IPV) and a weakened poliovirus given by mouth (OPV). The World Healt…
https://en.wikipedia.org/wiki/Polio_vaccine

menu_book

wikipedia NEUTRAL — Vivo Capital ("Vivo") is an American investment firm headquartered in Palo Alto, California. It is focused on making public and private investments in the healthcare and biotechnology industries.
https://en.wikipedia.org/wiki/Vivo_Capital

+ 3 more evidence sources

check_circle

Claim 7: “Eli Lilly on Tuesday announced plans to acquire three companies for almost $4 billion in cash”

CORROBORATED

Multiple independent news sources (WSJ and two other web search results) confirm Eli Lilly announced plans to acquire three companies for nearly $4 billion in cash.

travel_explore

web search NEUTRAL — 5 days ago ... Eli Lilly on Tuesday announced plans to acquire three companies for almost $4 billion in cash, as it looks to expand its research and ...
https://www.cnbc.com/2026/05/26/eli-lilly-stock-vaccine-deal…

travel_explore

web search NEUTRAL — 4 days ago ... Worth close to $4 billion combined, the acquisitions of Curevo, LimmaTech and Vaccine Co. signal plans by Lilly to build an infectious ...
https://www.biopharmadive.com/news/lilly-deal-acquire-curevo…

travel_explore

web search NEUTRAL — 5 days ago ... Indianapolis-based Lilly has agreed to acquire Curevo, LimmaTech Biologics and Vaccine Company, confirming an earlier report in The Wall Street ...
https://www.wsj.com/business/deals/eli-lilly-curevo-limmatec…

info

Claim 8: “The company said it had agreed deals to buy Curevo, LimmaTech Biologics and Vaccine Company for $1.5 billion, $780 million and $1.55 billion, respectively.”

SINGLE SOURCE

While multiple sources confirm the acquisition of Curevo, LimmaTech, and Vaccine Company, only one source specifically mentions the $1.5 billion figure for Curevo. The specific breakdown for LimmaTech ($780M) and Vaccine Company ($1.55B) is not corroborated across the provided evidence.

travel_explore

web search NEUTRAL — 4 days ago ... (Curevo), LimmaTech Biologics AG (LimmaTech Biologics), and Vaccine Company, Inc. (Vaccine Company), that expand its research and development ...
https://investor.lilly.com/node/54346/pdf

travel_explore

web search NEUTRAL — 2 days ago ... ... acquire LimmaTech Biologics AG, Curevo Inc., and Vaccine Company, Inc ... agreement, Lilly will pay up to $1.5 billion in cash to acquire Curevo.
https://www.bigmoleculewatch.com/2026/05/28/eli-lilly-expand…

travel_explore

check_circle

Claim 9: “Curevo has developed a vaccine for the prevention of shingles in adults”

CORROBORATED

Three separate web search results confirm that Curevo is developing a vaccine (amezosvatein) for the prevention of shingles in adults.

travel_explore

web search NEUTRAL — We are developing amezosvatein (CRV-101), a non-mRNA, adjuvanted subunit vaccine for shingles (herpes zoster) and chickenpox (varicella). ... developed for easy ...
https://curevovaccine.com/

travel_explore

web search NEUTRAL — 5 days ago ... Curevo's lead product is amezosvatein, a non-mRNA adjuvanted sub-unit vaccine to prevent shingles, a serious medical condition involving a ...
https://curevovaccine.com/uncategorized/curevo-to-be-acquire…

travel_explore

web search NEUTRAL — Curevo Vaccine is in Phase 2 of Shingles (CRV-101) study to evaluate the safety, tolerability and immunogenicity of the vaccine. Recruiting!
https://curevovaccine.com/amezosvatein-for-shingles/

info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.